Magnetic resonance technology is continually improving. Functional imaging techniques such as magnetic resonance spectroscopy, perfusion imaging, diffusion imaging, and diffusion tensor imaging are increasingly used in the diagnosis and treatment of brain tumors in children. However, estimate of tumor size remains the primary imaging endpoint in the evaluation of response to treatment, and validation across institutions and vendor platforms of magnetic resonance imaging functional parameters is necessary given the relatively uncommon occurrence of brain tumors in children. Pediatric neuroimaging can be challenging, and the optimal way to image children with tumors of the central nervous system is not uniformly applied across all centers. Application of proper scanning techniques and validation of functional imaging techniques should lead to improved care of children with central nervous system tumors.
Introduction
Throughout the past century, great strides have been made in the use of imaging techniques to localize and characterize brain tumors. Major milestones include the first reported injection of air into the lateral ventricles by Dandy in 1918 1 ; the routine use of pneumoencephalography and angiography starting in the 1940s; the arrival of computed tomography (CT) starting in the early 1970s; and, in the mid-1980s, the advent of magnetic resonance imaging (MRI) techniques. Our ability to evaluate pediatric patients with tumors of the central nervous system continues to evolve.
Magnetic resonance imaging is by far the most helpful and frequently used technique nowadays because of its exquisite intrinsic ability to differentiate tissue character.
In addition, MRI techniques can estimate multiple tissue parameters based on anatomy and functional/metabolic features of cerebral tissue. In this article, we focus on recent advances in the field of MRI and illustrate many of the technique's multiparametric capabilities. The technical and logistical challenges we face in increasing the application of these new techniques to the pediatric patient will be outlined.
Tumor Definition and Staging
In most children with central nervous system neoplasms, MRI clearly defines the location, size, and extent of a tumor. With the use of multichannel-phased array coils, images of very high anatomic resolution can now routinely be obtained. These high-quality images can be put to use in the operative setting, allowing the neurosurgeon the ability to perform image-guided surgical navigation. Magnetic resonance images are acquired intraoperatively (intraoperative MR) in an increasing number of medical centers.
In most centers, tumor size is assessed manually and reported using linear scalar measurements; to report tumor size and assess tumor response, bidirectional measurements (maximal length and perpendicular width) are preferred over unidimensional approaches (eg, response evaluation criteria in solid tumors). At many research centers, software programs are available to determine tumor volumes (3-dimensional) in a semiautomatic fashion. These techniques depend on clear margins between tumor tissue and surrounding parenchyma; this is simple for focal, well-marginated tumors. However, in the case of nonfocal tumors (such as malignant gliomas, optic pathway gliomas, and brainstem gliomas) conventional MRI techniques do not reliably define the extent of tumor and surrounding infiltration.
The MRI features of most pediatric brain tumors have been presented in the literature and are beyond the scope of this publication. At times these features are such that the tumor-type can be reliably suggested preoperativelyfor example, dysembryoplastic neuroepithelial tumor, pilocytic astrocytoma, and pleomorphic xanthoastrocytoma, among others. 2 Specific features have been described for medulloblastoma and primitive neuroectodermal tumor using fluid-attenuated inversion recovery MRI and diffusion imaging. 3 The various types of gliomas arising within the brainstem have been categorized, with clear impact on choice of treatment and outcome prediction. 4 In some cases, MRI characteristics are deemed sufficient to determine a specific tumor diagnosis, obviating the need for surgical biopsy prior to treatment-as in the case of infiltrative brainstem gliomas, optic pathway gliomas (especially in neurofibromatosis-1 patients), and certain tectal tumors.
In most instances, the ability to stage the extent of a tumor, and especially to detect the presence of subarachnoid metastatic disease, is more important than the preoperative determination of a particular tumor type. Pediatric brain tumors have a propensity to disseminate throughout the subarachnoid spaces, often at the time of presentation; this is reliably demonstrated on high-quality screening MRI studies of the central nervous system. Clear outcome differences have been demonstrated in regard to pediatric brain tumors depending on the presence or absence of dissemination. After resection or treatment, MRI can detect recurrences prior to symptoms. The impact of such surveillance scanning on outcome has been questioned, especially with regard to the surveillance of medulloblastoma after treatment; however, with improved surgical techniques and novel therapeutic regimens available for the salvage of recurrent tumors, the detection of smaller, presymptomatic recurrent tumor leads to improved outcomes. 5, 6 Anatomic imaging features such as the ones outlined so far in this text do not address many questions that come up in the care of a patient with a neoplasm of the central nervous system-issues such as histological grading of a tumor, selection of optimal biopsy sites and/or surgical approach, assessment of response to novel therapeutic approaches such as antiangiogenic agents, and assessment of the long-term effects of treatment on cognition. For these reasons, novel functional imaging techniques are increasingly applied. These functional imaging techniques can reflect tissue biochemistry (MR spectroscopy), capillary density (susceptibility perfusion techniques), capillary permeability (relaxivity imaging), and cellular density/tissue microarchitecture (diffusion imaging). In addition, cortical activation imaging (functional MRI) using blood oxygen levelÀdependent techniques can identify various loci of eloquent cerebral cortical function. Functional MRI is increasingly used in preoperative tumor assessment to guide the surgeon away from vital cortical regions 7 ; functional MRI, in conjunction with MR spectroscopy, has also been used in the treatment planning of malignant gliomas to improve radiation delivery using intensity-modulated radiation therapy. 7 Lastly, molecular imaging, long the domain of positron emission tomography (PET) and single-photo emission computed tomography (SPECT) imaging, is finding increasing applications with MRI techniques. Thus, the portfolio of MR functional imaging techniques is continually expanding. A discussion of principles, applications, and current limitations of these MRI techniques follows, with the exclusion of blood oxygen level-dependent functional MRI and molecular imaging.
Magnetic Resonance Spectroscopy
Magnetic resonance spectroscopy provides information about the presence and amount of hydrogen molecules attached to different cerebral molecular compounds. Hydrogen atoms located on different molecular compounds display intrinsic differences in resonant frequencies due to their differing molecular environment. A spectrum of resonant frequencies (or chemical shift) versus amplitude (concentration) can be generated that reflects the presence and concentration of these molecular compounds. The four most relevant compounds identified within cerebral tissue include N-acetyl-aspartate (NAA; a neuronal marker), choline (a marker of membraneassociated compounds), creatine and phosphocreatine (energy metabolites), and lactate (a byproduct of cerebral metabolism). Magnetic resonance spectroscopy can differentiate normal from tumor tissue, as tumor tissue in general shows elevation of choline and decrease in N-acetyl-aspartate.
Magnetic resonance spectroscopy has shown potential to differentiate tumor grades: in a study of 21 adult patients with grade II and III gliomas, choline and N-acetyl-aspartate levels correlated with both the degree of cellular density and the proliferative index. 9 Preoperative differentiation of grade II astrocytomas and oligodendrogliomas versus III astrocytomas was also feasible in a different study of 26 adult patients. 10 In children, MR spectroscopy is able to differentiate tumor from radiation necrosis ( Figure 1 ), monitor tumor response versus progression, and prognosticate overall survival. [11] [12] [13] In a study of 60 children with brain tumors, the metabolic profiles defined with quantitative short echo time MR spectroscopy revealed features of pediatric brain tumors that improve preoperative diagnosis. 14 Spectroscopy can be performed with single-voxel or multivoxel techniques. Single-voxel studies have faster acquisition times and better spectral resolution, and require a fairly large voxel size (6 to 8 cm 3 ); tissue composition within the voxel must be homogeneous, otherwise partial volume averaging of tissue of various compositions (eg, normal tissue, tumor, necrotic tissue) occurs and the spectrum has little value. In single-voxel imaging, the prescription (choosing the localization) of the voxel is totally operator-dependent (therefore not very reproducible). Spectroscopic analysis of a large volume of cerebral tissue with multiple small voxels (1 cm 3 ) is feasible with multivoxel studies (or magnetic resonance spectroscopic imaging). Magnetic resonance spectroscopic imaging allows for a more comprehensive examination of specific areas or regions of interest. Magnetic resonance spectroscopic imaging techniques are available in both 2 dimensions (single slice) and 3 dimensions (multislice or whole brain), and can be prescribed in a fairly standardized fashion. Magnetic resonance spectroscopic imaging of adult cerebral malignant gliomas can separate areas of high tumor grade from regions of lower grade. 15 With magnetic resonance spectroscopic imaging, MR spectroscopy becomes much more operator-independent; therefore, it can generate more reproducible data. Given the increased commercial availability of magnetic resonance spectroscopic imaging software, the reliability and value of magnetic resonance spectroscopic imaging in the evaluation and monitoring of pediatric central nervous system tumors could realistically be addressed in a multicenter study.
Perfusion Imaging
Perfusion imaging can be performed with techniques based on dynamic susceptibility contrast or based on vascular permeability. Dynamic susceptibility contrast techniques assess cerebral tissue perfusion following a dynamic injection of gadolinium. During the first-pass transit of contrast through cerebral capillaries, which lasts anywhere from 5 to 15 s, gadolinium is restricted to the intravascular space. This intravascular restriction gives rise to signal inhomogeneity within image voxels (ie, a susceptibility effect), which is reflected as signal loss on susceptibility-sensitive T2 (T2*) imaging techniques. A curve showing concentration of gadolinium over time can be generated. The concentration of gadolinium is a direct reflection of the capillary density. From this, the regional cerebral blood volume can be determined, which corresponds to the volume of blood within brain tissue (Figure 2). Regional cerebral blood volume can reflect the neovascularization associated with tumor growth (tumor angiogenesis); in adults with glial tumors, angiogenesis is highly correlated to tumor grade, and the regional cerebral blood volume of most high-grade glial tumors is greater than that of low-grade tumors. 16 Using a combined first-pass gradient-echo and spin-echo method, tumor grade was predicted with high accuracy in a study of 73 adult patients with gliomas. 17 In addition, the mean vessel diameter can be determined with this combined gradient-spin echo approach (mean vessel diameter and tumor grade were highly correlated 17 ). In a study of 35 patients (including 5 children) with low-grade gliomas (excluding pilocytic astrocytoma), dynamic susceptibility contrast perfusion imaging helped to identify tumors that progressed rapidly and a subset of gliomas that had a propensity for malignant transformation. 18 Dynamic susceptibility contrast perfusion imaging can be used to select stereotactic biopsy sites by guiding the surgeon to the more capillary dense (ie, malignant) portion of a tumor. Tumor response to treatment can be assessed and the differentiation of tumor from radiation necrosis / scar tissue discerned, as the latter has low capillary density, in contrast to the high density associated with a malignant tumor. The application of perfusion imaging to evaluate children on antiangiogenic agents is of great interest: when effective, these cytostatic agents might not decrease tumor size but instead prevent progression. The standard anatomic measurements of tumor size used to assess the efficacy of cytotoxic regimens, therefore, may not apply to antiangiogenic regimens; however, in response to an antiangiogenic agent, a decrease in capillary density/regional cerebral blood volume demonstrable by dynamic susceptibility contrast imaging is expected. 19 For many reasons, dynamic susceptibility contrast perfusion studies do not consistently generate usable data. First, a larger-bore intravenous catheter must be placed (preferably in the antecubital fossa) to safely deliver the injection of 3 to 4 cc/s of gadolinium necessary to generate a well-defined first-pass curve, which is not always easy, especially in sicker children or those on steroids. Second, susceptibility artifacts are not negligible, as dynamic susceptibility contrast perfusion utilizes an echo planar technique (echo planar images are prone to image distortion by susceptibility artifacts); studies performed on children with orthodontic braces or in the presence of significant amounts of intracranial/intratumoral hemorrhage are often useless. Finally, gadolinium contrast can leak through tumor capillaries; such leakage can result in an underestimation of regional cerebral blood volume, as the computations performed to process the susceptibility T2* signal assumes that the contrast remains confined to the capillary. 20 Permeability-based perfusion techniques take advantage of leakage of gadolinium through tumor vessel walls. In healthy cerebral capillaries, the blood-brain barrier prevents gadolinium leakage and the injected contrast does not leak into the interstitium. Tumor capillaries have disrupted or absent blood-brain barriers, which allows contrast to leak outside the vessel into tissue interstitium. The rate of leakage is proportional to the permeability of the capillary wall. Permeability imaging, also known as relaxivity imaging, is a T1-weighted technique in which a curve of dynamic signal intensity (ie, enhancement) versus time is generated. The slope of enhancement reflects the degree of permeability of capillaries. The intensity of initial enhancement reflects tissue vascularity: fractional blood volume can be extrapolated. 21 Fractional blood volume is a fairly good estimate of the regional cerebral blood Figure 2 . Axial T2-weighted image (A) of a patient with an infiltrative brainstem glioma. Regional cerebral blood volume map of a dynamic susceptibility contrast perfusion study (B) reveals significant increase in signal, reflective of high capillary density. volume data obtained with susceptibility perfusion. 22 In adult patients with malignant glial tumors, this technique has been shown to be useful in grading gliomas and in assessing response to anti-angiogenic therapies. 21 Permeability-based perfusion techniques have many advantages over dynamic susceptibility contrast techniques: studies have superior anatomic resolution, and do not suffer from the drawback of T2* susceptibility artifacts observed on the echo planar images. Furthermore, injection rates are much more acceptable, 1 to 2 mL/s, thus more tolerable to the patient; central lines or peripherally inserted central catheter lines can be used for venous access. As permeability based approaches can be more consistently performed, they may become the perfusion technique of choice for multicenter central nervous system tumor evaluations.
Diffusion Imaging
Diffusion imaging investigates molecular translational movements (ie, Brownian motion) of water molecules. Brownian motion produces signal loss proportional to the degree of molecular translation/diffusion. Within the cerebral milieu, cellular membranes and other macromolecular structures restrict water diffusion, which results in increased signal on diffusion imaging (less diffusion means less signal loss secondary to spin dephasing). Thus, signal on diffusion images can reflect cellular density and microarchitecture. The apparent diffusion coefficient is a measure of the ability of tissue to restrict water diffusion. Apparent diffusion coefficient decreases with increasing cellularity (Figure 3) . In a study of 37 adult patients with malignant cerebral gliomas (grades III and IV), the apparent diffusion coefficient was shown to adversely correlate with the grade of tumor and the cellular proliferation Ki-67 labeling index. 23 Furthermore, increase in apparent diffusion coefficient, reflecting decreased cellularity, has been observed as tumors respond to treatment.
Diffusion imaging can also be used to assess the microscopic structural integrity of white matter tracts as the movement of water is restricted by the myelin sheath surrounding the axon and by the cell membrane. Diffusion of water molecules is less restricted in a direction parallel to the long axis of axons and more restricted in the direction perpendicular to the axon. Anisotropy, an aggregate measure of the magnitude of displacement across all 3 dimensions, is directly correlated with the degree of myelination as assessed using myelin-sensitive histological staining. 24 Using information gleaned from the size, shape, orientation, and distribution (or special pattern) of diffusion ellipsoids within an imaged volume, one can characterize features of water diffusion within a voxel-the diffusion tensor. A voxel-by-voxel analysis of anisotropy can be performed: diffusion tensor imaging. Connectivity maps (ie, tractography) that demonstrate the long association (axonal) pathways that convey cortical connections as tracklike structures can also be generated.
Diffusion tensor imaging tractography is used to plan the surgical approach to a focal tumor: important association pathways (eg, pyramidal, optic) can be localized in relation to a tumor, helping the surgeon to avoid injury to these white matter tracts. Diffusion tensor imaging also shows promise as tool to evaluate the presence and extent of tumoral invasion. Whereas focal (well-marginated) tumors should displace but not disrupt axons outside their borders, the microscopic tumor extension of infiltrative tumors is expected to disrupt local axonal structures. [25] [26] [27] Diffusion tensor imaging evaluation of axonal integrity has also been used to assess global white matter injury in children who have received whole brain radiation. In a study of survivors of acute lymphoblastic leukemia, loss of anisotropy within cerebral white matter was highly correlated with IQ scores, independent of age. 28 Current diffusion tensor imaging tractography techniques have their limitations. The exact nature of the tract-like structures depicted is not known (they surely do not represent axons proper). Resolution is limited, as only the larger association pathways can be identified. Resolution is lost when fibers with intersecting trajectories (crossing fibers) are present within a voxel. More powerful diffusion techniques are currently being investigated, including diffusion spectrum imaging, which can resolve crossing fibers at the scale of single MRI voxels. Diffusion spectrum imaging should vastly increase the intrinsic resolution of diffusion imaging techniques and lead to improved applications in surgical planning, evaluation of tumor infiltration, and assessment of white matter damage. 29 
Best Practice in Pediatric Neuro-oncologic Imaging
Tumors of the central nervous system are relatively uncommon in infants and children. In addition, a wide variety of histologies are encountered, including unique pathological entities seen in infants and young children. This wide histological variety is reflected by a wide range of imaging appearances of the lesions at MRI. As a result, it is difficult for individual centers to collect a significant experience for a particular tumor type. Multicenter collaboration is clearly needed in pediatric neuro-oncology to advance the field and improve outcomes. The Children's Oncology Group includes most pediatric oncologic centers in North America and many beyond; large numbers of patients can be entered in treatment protocols in which imaging research questions can be addressed. A smaller collaborative croup, the Pediatric Brain Tumor Consortium, has been in existence for approximately a decade and currently includes 11 centers. Uniform imaging protocols are now required as part of the evaluation and follow-up of patients entered on Children's Oncology Group and Pediatric Brain Tumor Consortium treatment protocols. Uniformity of imaging acquisition parameters allows for more rigorous central review of studies.
Central radiographic reviews by designated radiologists are mandated in most Children's Oncology Group and Pediatric Brain Tumor Consortium study protocols of children with central nervous system tumors. Although central analysis of anatomic images is fairly straightforward, analysis of functional imaging studies is more problematic. Some functional techniques are operator-dependent (eg, single-voxel spectroscopy, susceptibility perfusion) and not all techniques are digital imaging and communications in medicine compliant, so compatibility across vendor platforms becomes an issue. Furthermore, regular upgrades by MRI vendors can render prior study results obsolete, making it difficult to accumulate historical data. Centralized reviews of magnetic resonance studies performed and interpreted across a broad range of academic and regional/community centers have also demonstrated a wide range in the quality of imaging studies performed on children, with demonstrable impact on patient outcome. For example, in the Children's Oncology Group 9961 study (a study of more than 400 children with average risk medulloblastoma requiring a clear demonstration by MRI of small (<1.5 cm 2 ) or absent tumor residual after surgery and absence of tumor dissemination/metastatic disease), two pediatric neuroradiologists performed a central review of all the central nervous system imaging studies. Fifteen percent of MRI studies acquired at the time of patient entry to the treatment protocol were judged to be of inadequate quality to properly evaluate for residual tumor and tumor dissemination; poor technique or excessive motion were the most common causes. Furthermore, 7% of registered patients were declared ineligible due to the presence of significant residual tumor or of tumor dissemination not identified at the time of initial interpretation. The event-free survival for these patient groups was significantly poorer than for the patients who were properly evaluated and entered on study. The 5-year event-free survival was 83% for the appropriately entered patients, 73% for the patients with study entry MRI scans judged to be of inadequate quality, 75% for patients with local residual tumor >1.5 cm 2 , and 36% for the patients with disseminated disease. 30 Technically well-performed studies that are correctly interpreted by physicians who have a good understanding of study eligibility criteria are integral to collaborative studies. With greater understanding of these issues by the imaging and oncologic communities, improved patient outcome and more rapid completion of treatment studies can be expected (as fewer patients with inadequate staging studies or patients who are not eligible would be entered on study). Upfront, rapid centralized assessment (rapid review) by a designated study radiologist of imaging studies acquired on patients entered in collaborative studies may even be indicated.
Conclusion
Magnetic resonance technology is improving, with faster gradients, more sensitive coils, and improved software.
Evaluation of tumor size remains the primary imaging endpoint in the evaluation of response for most pediatric patients with central nervous system neoplasms. As evident from the literature, multiple MRI functional parameters have been validated, primarily in adult central nervous system tumor studies. These techniques need validation across institutions and vendor platforms in the pediatric population. Greater use of these functional parameters will increase the impact of imaging on patient care. More powerful magnets (3 Tesla instead of 1.5 Tesla) will further advance the field of imaging; advantages of the 3 Tesla systems include greater speed and resolution, increased sensitivity to gadolinium enhancement, and improved spectral resolution (with magnetic resonance spectroscopy).
The optimal way to image children with a central nervous system tumor is not uniformly applied across all centers. Pediatric neuroimaging can be challenging, primarily because of issues of sedation, patient size, and physiologic motion. Dissemination throughout the subarachnoid spaces is not always recognized. Criteria for study eligibility and response determination are not always understood. Increased awareness of these factors, validation of functional imaging techniques, and the increased availability of electronic distribution of imaging studies should lead to improved care of children with central nervous system tumors.
